Authors : K . Gnanankitha; A . Lahari; V. Poojitha; Paila. Bhanuji Rao; Nimmala. Phani Satyavathi

Volume/Issue : Volume 10 - 2025, Issue 2 - February

Google Scholar : https://tinyurl.com/kftt5k3v

Scribd : https://tinyurl.com/znaz4bcs

DOI : https://doi.org/10.5281/zenodo.14959376

Abstract : Platinum-based chemotherapy agents, such as cisplatin, carboplatin, and oxaliplatin, are essential in cancer treatment due to their ability to disrupt DNA replication and induce the death of tumor cells. However, their use is often linked with significant hematologic toxicities, particularly myelosuppression, which can lead to conditions like anemia, neutropenia, and thrombocytopenia. These side effects may require dose adjustments, treatment delays, and increase the likelihood of infections and bleeding complications. This article delves into the mechanisms of hematotoxicity linked to platinum-based treatments, including bone marrow suppression, oxidative damage, and DNA crosslinking, all of which hinder normal blood cell production. It also reviews various management strategies, such as modifying drug doses, providing supportive treatments (e.g., G-CSF, erythropoietin-stimulating agents, and transfusions), and conducting regular hematologic monitoring. Ongoing research is focused on improving drug formulations, optimizing combination therapies, and developing protective strategies to reduce toxicity while preserving the drugs’ therapeutic effects. A personalized approach to chemotherapy may reduce hematologic side effects and enhance patient outcomes in cancer care.

Keywords : Platinum-Based Chemotherapy, Cisplatin, Carboplatin, Oxaliplatin, Hematologic Toxicity, Myelosuppression, Anemia, Neutropenia, Thrombocytopenia, DNA Crosslinking, Chemotherapy Side Effects, Cancer Treatment, Bone Marrow Suppression, Supportive Care In Oncology.

References :

1. Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7(8), 573–584.
2. Galanski, M., Jakupec, M. A., & Keppler, B. K. (2005). Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Current Medicinal Chemistry, 12(18), 2075–2094.
3. Pabla, N., & Dong, Z. (2008). Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney International, 73(9), 994–100.
4. Go, R. S., & Adjei, A. A. (1999). Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. Journal of Clinical Oncology, 17(1), 409–42
5. Ardalan, B., Flores, J., Shostak, Y., & Ardalan, B. (1990). Hematologic toxicity of carboplatin. Cancer Treatment Reviews, 17(1), 7–14.
6. Wang, D., & Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery, 4(4), 307–320
7. Galsky, M. D., & Vogelzang, N. J. (2010). Myelosuppression in platinum-based chemotherapy: Strategies for prevention and management. Cancer Treatment Reviews, 36(1), 24–30
8. Oun, R., Moussa, Y. E., & Wheate, N. J. (2018). The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Transactions, 47(19), 6645–6653.
9. Markman, M. (2003). Toxicities of the platinum antineoplastic agents. Expert Opinion on Drug Safety, 2(6), 597–607.
10. Dilruba, S., & Kalayda, G. V. (2016). Platinum-based drugs: past, present and future. Cancer Chemotherapy and Pharmacology, 77(6), 1103–1124.
11. Wagstaff, A. J., Ward, A., Benfield, P., & Heel, R. C. (1989). Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37(2), 162–198.
12. Theile, D., & Kos, M. (2016). Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. Toxicology Letters, 242, 47–52.
13. Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., & Harrap, K. R. (1985). Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treatment Reviews, 12(Suppl A), 51–57.
14. Oun, R., & Wheate, N. J. (2018). Correction: The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Transactions, 47(23), 73
15. Beveridge, R. A., Miller, J. A., Kales, A. N., Binder, R. A., Robert, N. J., Harvey, J. H., Windsor, K., Gore, I., Cantrell, J., Thompson, K. A., Taylor, W. R., Barnes, H. M., & Schiff, S. A. (1998). A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Investigation, 16, 366–373.
16. Urbonas, V., Eidukaite, A., & Tamuliene, I. (2012). The diagnostic value of interleukin-6 and interleukin-8 for early prediction of bacteremia and sepsis in children with febrile neutropenia and cancer. Journal of Pediatric Hematology/Oncology, 34, 122–127.
17. Hao, J., Sun, L., Huang, H., Xiong, G., Liu, X., Qiu, L., Chen, G., Dong, B., Li, Y., Chen, W., Buechler, Y., Sun, J., Shen, C., & Luo, Q. (2004). Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Radiation Research, 162, 157–163
18. Azuaje, F. J., Zhang, L., Devaux, Y., & Wagner, D. R. (2011). Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs.
19. Rosenberg B, et al. (1965). Nature.
20. Dasari S, Tchounwou PB. (2014). Front Pharmacol.
21. Kelland L. (2007). Nat Rev Cancer.
22. Wang D, Lippard SJ. (2005). Nat Rev Drug Discov.
23. Stewart DJ. (2007). Cancer Chemother Pharmacol.
24. Einhorn LH. (2002). J Clin Oncol.
25. Marullo R, et al. (2013). J Cell Mol Med.
26. Deavall DG, et al. (2012). J Toxicol.
27. Rybak LP, et al. (2019). Antioxid Redox Signal.
28. Oun R, et al. (2018). Cancer Chemother Pharmacol.
29. Arany I, Safirstein RL. (2003). Kidney Int.
30. Ghosh S. (2019). J Hematol Oncol.
31. Crawford J, et al. (2004). J Clin Oncol.
32. Visvader JE, et al. (2011). Blood.
33. DeVita VT, et al. (2011). Cancer: Principles and Practice of Oncology.
34. Smith TJ, et al. (2015). J Clin Oncol.
35. Yousef MI, et al. (2009). Toxicology.
36. Crawford J, et al. (2006). Support Care Cancer.
37. Pabla N, Dong Z. (2008). Toxicol Sci.
38. Chovanec M, et al. (2017). Nat Rev Urol.